Navigation Links
Alexza Pharmaceuticals to Present at the 2013 Wedbush Life Sciences Management Access Conference
Date:8/6/2013

MOUNTAIN VIEW, Calif., Aug. 6, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company will participate in the 2013 Wedbush Life Sciences Management Access Conference, being held in New York, New York, August 13 - 14, 2013.  Thomas B. King, Alexza President and CEO, will present at the conference.  The Alexza corporate presentation will be Wednesday, August 14, 2013 at 8:35 a.m. Eastern Time.  The presentation will be webcast live.

To access the presentation via the Web, please go to the Alexza Investor Relations tab at www.alexza.com or directly http://wsw.com/webcast/wedbush25/ALXA.  A replay of the webcast will be available approximately 24 hours after the presentation and archived for 30 days.

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions, including agitation, acute repetitive seizures and insomnia.  Alexza's products are based on the Staccato® system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.

ADASUVE® (Staccato loxapine), Alexza's first approved product, was approved by the U.S. Food and Drug Administration in December 2012 and by the European Medicines Agency in February 2013.  Teva Pharmaceutical USA Inc. is Alexza's commercial partner for ADASUVE in the U.S.  Grupo Ferrer Internacional, S.A. is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.  For more information about ADASUVE, please visit www.adasuve.com

ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.

Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability for Alexza and our partners, Teva and Ferrer, to effectively and profitably commercialize ADASUVE, estimated product revenues and royalties associated with the sale of ADASUVE, the adequacy of the Company's capital to support the Company's operations, and the Company's ability to raise additional funds and the potential terms of such potential financings. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Reports 2013 First Quarter Financial Results
2. Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy
3. Alexza to Report 2013 First Quarter Financial Results on Thursday, May 9, 2013
4. Alexza Reports 2012 Fourth Quarter and Full Year Financial Results
5. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
6. Alexza to Report 2012 Year-End Financial Results on Tuesday, March 26, 2013
7. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
8. Alexza Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
9. Alexza Reports 2012 Second Quarter Financial Results and Provides Business Update
10. Alexza Announces Management Promotions
11. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017 LG Innotek today announced that the company ... As its sterilization performance is 1.5 times higher than the competitor,s ... rays in the range of 200 -- 280nm, allowing it to be ... destroying their DNA. LG Innotek,s product emits UV in the range ... Until ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Cardiac Prosthetic Devices Market is ... next decade to reach approximately $8.9 billion by 2025. ... the given segments on global as well as regional levels presented ...
(Date:2/23/2017)... February 23, 2017 Tillotts Pharma ... Berlin office was opened in ... . The portfolio includes Entocort ® for the ... treatment of ulcerative colitis, and VistaPrep ® for ... Swiss specialty pharmaceutical company focused on the treatment of ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... clinician-based audience, will be participating in Rare Disease Day events, hosted by the ... addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will be ...
(Date:2/23/2017)... Fair Lawn, NJ (PRWEB) , ... February 23, ... ... specializing in thought leadership , media relations, content marketing, social media ... Vermont. With several clients already in the state and in nearby New Hampshire, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing LLC ... converge and explore the world from different perspectives. By providing a place for ... gain understanding, increase empathy, and find greater happiness. , "Our approach to ...
(Date:2/23/2017)... Lincoln, RI (PRWEB) , ... February 23, 2017 ... ... announced today a new partnership with the Rhode Island Consortium for Autism Research ... provide an opportunity for children with autism spectrum disorder (ASD) to see films ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today ... efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three ... enrolling children across the United States. , “There are currently no approved drugs ...
Breaking Medicine News(10 mins):